Teva Pharmaceuticals Australia Pty Ltd

Organization

Macquarie Park, AU

Organizations

Please log in for detailed analytics

Patents Grantslast 30 patents

Information Patent Grant
Anti-CD47 combination therapy
- Patent number 12,258,401
- Issue date Mar 25, 2025
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Sarah Lee Pogue
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-CD47 combination therapy
- Patent number 11,618,784
- Issue date Apr 4, 2023
- Teva Pharmaceuticals Australia Pty Ltd.
- Sarah Lee Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Interferon alpha 2B variants
- Patent number 11,319,356
- Issue date May 3, 2022
- Teva Pharmaceuticals Australia Pty Ltd.
- Collette Behrens
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Combination of lenalidomide and polypeptide construct, and uses the...
- Patent number 11,253,591
- Issue date Feb 22, 2022
- Teva Pharmaceuticals Australia Pty Ltd.
- Sarah L. Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
- Patent number 11,117,975
- Issue date Sep 14, 2021
- Teva Pharmaceuticals Australia Pty Ltd.
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fusions of antibodies to CD38 and attenuated interferon alpha
- Patent number 10,981,986
- Issue date Apr 20, 2021
- Teva Pharmaceuticals Australia Pty Ltd.
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies against TL1a and uses thereof
- Patent number 10,822,422
- Issue date Nov 3, 2020
- Teva Pharmaceuticals Australia Pty Ltd.
- Lynn Dorothy Poulton
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Interferon alpha 2B variants
- Patent number 10,544,199
- Issue date Jan 28, 2020
- Teva Pharmaceuticals Australia Pty Ltd.
- Collette Behrens
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
- Patent number 9,963,515
- Issue date May 8, 2018
- Teva Pharmaceuticals Australia Pty Ltd.
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination of lenalidomide and polypeptide construct, and uses the...
- Patent number 9,636,334
- Issue date May 2, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- Sarah L. Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fusions of antibodies to CD38 and attenuated interferon alpha
- Patent number 9,611,322
- Issue date Apr 4, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Modified antibody with improved half-life
- Patent number 9,505,826
- Issue date Nov 29, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- David Wilson
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Treatment of cancer involving mutated KRAS or BRAF genes
- Patent number 8,932,588
- Issue date Jan 13, 2015
- Teva Pharmaceuticals Australia Pty Ltd
- Norbert A. Kienzle
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Humanized antibodies with anti-tumor activity
- Patent number 8,901,279
- Issue date Dec 2, 2014
- Teva Pharmaceuticals Australia Pty Ltd
- Adam W. Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
ANTIBODIES AGAINST TL1A AND USES THEREOF
- Publication number 20240141053
- Publication date May 2, 2024
- Teva Pharmaceuticals Australia Pty Ltd
- Lynn Dorothy POULTON
- G01 - MEASURING TESTING
Information Patent Application
ANTI-CD47 COMBINATION THERAPY
- Publication number 20220259311
- Publication date Aug 18, 2022
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Sarah Lee Pogue
- C07 - ORGANIC CHEMISTRY
Information Patent Application
INTERFERON ALPHA 2B VARIANTS
- Publication number 20220220184
- Publication date Jul 14, 2022
- Teva Pharmaceuticals Australia Pty Ltd
- Collette Behrens
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES AGAINST TL1A AND USES THEREOF
- Publication number 20210347904
- Publication date Nov 11, 2021
- Teva Pharmaceuticals Australia Pty Ltd
- Lynn Dorothy POULTON
- G01 - MEASURING TESTING
Information Patent Application
INTERFERON ALPHA 2B VARIANTS
- Publication number 20200102364
- Publication date Apr 2, 2020
- Teva Pharmaceuticals Australia Pty Ltd
- Collette Behrens
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-CD47 COMBINATION THERAPY
- Publication number 20200010544
- Publication date Jan 9, 2020
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Sarah Lee POGUE
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THE...
- Publication number 20190151447
- Publication date May 23, 2019
- Teva Pharmaceuticals Australia Pty Ltd
- Sarah L. Pogue
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
- Publication number 20180305460
- Publication date Oct 25, 2018
- Teva Pharmaceuticals Australia Pty Ltd
- Adam Clarke
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA
- Publication number 20170233449
- Publication date Aug 17, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THE...
- Publication number 20170202962
- Publication date Jul 20, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- Sarah L. Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
POLYPEPTIDE CONSTRUCTS AND USES THEREOF
- Publication number 20160367695
- Publication date Dec 22, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Antibodies Against TL1a and Uses Thereof
- Publication number 20160333104
- Publication date Nov 17, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- Lynn Dorothy Poulton
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
INTERFERON ALPHA 2B VARIANTS
- Publication number 20160122410
- Publication date May 5, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- Collette Behrens
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
- Publication number 20160068612
- Publication date Mar 10, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination of Lenalidomide and Polypeptide Construct, and Uses The...
- Publication number 20150313965
- Publication date Nov 5, 2015
- Teva Pharmaceuticals Australia Pty, Ltd
- Sarah L. Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES TO CD1d
- Publication number 20140286957
- Publication date Sep 25, 2014
- Teva Pharmaceuticals Australia Pty Ltd
- Jonathan Kannan Nambiar
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES AGAINST TL1a AND USES THEREOF
- Publication number 20140255302
- Publication date Sep 11, 2014
- Teva Pharmaceuticals Australia Pty Ltd
- Lynn Dorothy Poulton
- G01 - MEASURING TESTING
Information Patent Application
POLYPEPTIDE CONSTRUCTS AND USES THEREOF
- Publication number 20140248238
- Publication date Sep 4, 2014
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- C07 - ORGANIC CHEMISTRY

Trademarklast 30 trademarks

Information Trademark
87310256 - SUPERHUMANIZATION
- Serial number 87310256
- Filing date Jan 23, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- 40 - Treatment of materials

Teva Pharmaceuticals Australia Pty Ltd

Organization

Patents Grantslast 30 patents

Anti-CD47 combination therapy

Anti-CD47 combination therapy

Interferon alpha 2B variants

Combination of lenalidomide and polypeptide construct, and uses the...

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Fusions of antibodies to CD38 and attenuated interferon alpha

Antibodies against TL1a and uses thereof

Interferon alpha 2B variants

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Combination of lenalidomide and polypeptide construct, and uses the...

Fusions of antibodies to CD38 and attenuated interferon alpha

Modified antibody with improved half-life

Treatment of cancer involving mutated KRAS or BRAF genes

Humanized antibodies with anti-tumor activity

Patents Applicationslast 30 patents

ANTIBODIES AGAINST TL1A AND USES THEREOF

ANTI-CD47 COMBINATION THERAPY

INTERFERON ALPHA 2B VARIANTS

ANTIBODIES AGAINST TL1A AND USES THEREOF

INTERFERON ALPHA 2B VARIANTS

ANTI-CD47 COMBINATION THERAPY

COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THE...

ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B

FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA

COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THE...

POLYPEPTIDE CONSTRUCTS AND USES THEREOF

Antibodies Against TL1a and Uses Thereof

INTERFERON ALPHA 2B VARIANTS

ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B

Combination of Lenalidomide and Polypeptide Construct, and Uses The...

ANTIBODIES TO CD1d

ANTIBODIES AGAINST TL1a AND USES THEREOF

POLYPEPTIDE CONSTRUCTS AND USES THEREOF

Trademarklast 30 trademarks

87310256 - SUPERHUMANIZATION